Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Isoalantolactone** is a natural sesquiterpene lactone of the eudesmanolide group, predominantly isolated from the roots of Inula helenium and other plants of the Asteraceae family[1][2]. It exhibits a broad range of pharmacological activities, including antitumor (notably proliferation inhibition, cell cycle arrest, ROS overproduction, apoptosis induction), anti-inflammatory (via NF-κB inhibition), antimicrobial, antihelminthic, antioxidant, and neuroprotective properties[1][3][5]. Mechanistically, isoalantolactone is known to induce apoptosis in cancer cells (for example, pancreatic cancer) by increasing reactive oxygen species and inhibiting the Wnt-β-catenin pathway as well as the AMPK-Skp2-Akt axis[3]. Its principal molecular pharmacodynamic actions are related to the modulation of oxidative stress and inhibition of specific intracellular signaling pathways linked to cell survival and inflammation[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoalantolactone.